<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538848</url>
  </required_header>
  <id_info>
    <org_study_id>4010.PCT001</org_study_id>
    <nct_id>NCT02538848</nct_id>
  </id_info>
  <brief_title>Study of HTD4010 in Healthy Volunteers</brief_title>
  <official_title>A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in
      healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety, tolerability and pharmacokinetics(PK) assessments are the outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity and causality of adverse events</measure>
    <time_frame>One day in SAD</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>50mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 50mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 100mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 200mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 300mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD4010</intervention_name>
    <description>injectable solution</description>
    <arm_group_label>50mg in SAD</arm_group_label>
    <arm_group_label>100mg in SAD</arm_group_label>
    <arm_group_label>200mg in SAD</arm_group_label>
    <arm_group_label>300mg in SAD</arm_group_label>
    <other_name>analog of INGAP peptide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For volunteers in SAD:

        Inclusion Criteria:

          1. Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2

          2. Non-diabetic, fasting plasma glucose &lt; 5.6 mmol/L

          3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or
             post-menopausal for ≥12 months.

             Males must be surgically sterile, abstinent or if engaged in sexual relations of
             child-bearing potential, the participant and his partner must be using an acceptable,
             highly effective, contraceptive method from screening and for a period of 60 days
             after the last dose of Study Drug.

          4. Ability to provide written informed consent.

        Exclusion Criteria:

          1. Systolic blood pressure &gt;160 mmHg and/or diastolic blood pressure &gt;90 mmHg at
             screening.

          2. Pregnant or lactating women

          3. Participation in an investigational study within 30 days prior to dosing or 5
             half-lives within the last dose of investigational product whichever is longer.

          4. Current use of any prescription or over-the-counter (OTC) medications, including
             herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives,
             whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the
             study at Investigator discretion.

          5. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.

          6. History of any major surgery within 6 months prior to Screening

          7. History of any serious adverse reaction or hypersensitivity to any of the product
             components.

          8. Use of parenterally administered proteins or antibodies within 12 weeks of screening.

        etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janakan Krishnarajah, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Perth</city>
        <zip>WA6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

